Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
MENLO PARK, Calif., May 09, 2017 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report preliminary results of the Corplex Donepezil pilot bioequivalence study as well as financial results for the second quarter ended March 31, 2017 on Thursday, May 11, 2017 before the open of the U.S. financial markets. Corium will host a conference call and live audio webcast at 8:30 a.m. Eastern time, 5:30 a.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 20268962. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan Pietropaolo [email protected] (201) 923-2049
